Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Early Phase 2 data published in the New England Journal of Medicine in 2023 showed considerable promise, but retatrutide has not yet received approval from the MHRA or EMA
But there are three very important things to remember here
Common side effects include: Injection site reactions mild pain, redness, swelling, or bruising at the injection site, typically resolving within a few days Headache usually transient and manageable with standard analgesia Nausea or dizziness particularly in the initial treatment phase Skin reactions including itching, mild rash, or acneiform eruptions Temporary urine discolouration red or orange urine is harmless and expected Diarrhoea or flushing usually mild and self-limiting In patients with severe megaloblastic anaemia, low potassium levels (hypokalaemia) may occur during initial intensive treatment, but this is uncommon in routine maintenance therapy
AstraZeneca plc Boehringer Ingelheim Amgen Inc
US$ 28.44
US$ 20.39
US$ 23.69
